Source comparison
The Unfiltered Truth About CJC-1295 vs HGH Therapy
Here's the honest answer: neither compound is a muscle-building miracle. The marketing around both peptides and HGH oversells what the clinical data actually shows. Yes, IGF-1 elevation supports anabolism. But it's not the primary driver of muscle hypertrophy
This comparison does not assign a generated winner or score.
- Here's the honest answer: neither compound is a muscle-building miracle. The marketing around both peptides and HGH oversells what the clinical data actually shows. Yes, IGF-1 elevation supports anabolism. But it's not the primary driver of muscle hypertrophy in trained individuals. Progressive mechanical tension (heavy resistance training), adequate protein intake (1.6–2.2 g/kg), and caloric surplus still determine 90% of your lean mass gains. GH and IGF-1 optimise recovery and tissue repair, which indirectly supports training volume. But they don't override poor programming or inadequate nutrition.
- The evidence for performance enhancement in non-GH-deficient adults is inconsistent at best. A 2018 systematic review in the British Journal of Sports Medicine analysed 44 controlled trials and concluded that rhGH increased lean body mass by 1.5–2.0 kg but produced no significant strength or endurance improvements. The lean mass gain was attributed to connective tissue and water retention, not contractile muscle protein. Peptide secretagogues like CJC-1295 have even less robust human performance data. Most studies are underpowered pilot trials in elderly populations.
- What we mean sincerely: if you're considering either protocol, the decision should be based on hormone optimisation for recovery and longevity. Not physique transformation. CJC-1295 preserves natural function and costs less; HGH produces higher IGF-1 peaks but suppresses endogenous secretion and carries greater metabolic risk. Neither replaces disciplined training and nutrition.
- Anyone exploring research peptides like CJC-1295 must recognise they're operating in a regulatory grey zone. These compounds are not FDA-approved for human therapeutic use. They're sold exclusively for research purposes. Facilities like Real Peptides synthesise peptides under strict quality control for laboratory research, but that doesn't make them prescription drugs. HGH is a Schedule III controlled substance. Possession without a valid prescription is a federal offence. Weigh the legal and health risks carefully before proceeding with either compound.
- If you're comparing CJC-1295 vs HGH therapy because you suspect growth hormone deficiency (fatigue, poor recovery, declining lean mass despite training), the correct first step is diagnostic testing with an endocrinologist. Stimulation tests (arginine-GHRH, glucagon stimulation) and IGF-1 measurement determine whether you have true GH insufficiency. In which case prescription HGH is medically indicated and insurance may cover it. Self-administration of research peptides or black-market HGH without baseline labs and medical oversight introduces unnecessary risk.
- For individuals without clinical deficiency who want to optimise recovery and tissue repair through peptide research, CJC-1295 offers a more conservative entry point than exogenous HGH. It preserves your natural pulse rhythm, costs significantly less, requires fewer injections, and avoids the pituitary suppression that makes HGH difficult to discontinue. That doesn't mean it's risk-free. Any compound that alters hormone signalling carries unknowns, especially in long-term use beyond 24 months where human data remains sparse.